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Abstract: MIRO1 and MIRO2 (mitochondrial Ras homolog gene family, member T1 and T2) also referred to as RHOT1 
and RHOT2, belong to the mitochondrial Rho GTPase family and are involved in axonal transport of mitochondria in neu-
rons. Because mitochondrial dysfunction is strongly implicated in Parkinson’s disease (PD), MIRO1 and MIRO2 can be 
considered as new candidate genes for PD. We analyzed two non-synonymous polymorphisms and one synonymous 
polymorphism in MIRO1 and two non-synonymous polymorphisms in MIRO2, in a Swedish Parkinson case-control mate-
rial consisting of 241 patients and 307 neurologically healthy controls. None of the analyzed polymorphisms in MIRO1 
and MIRO2 were significantly associated with PD. Although we did not find a significant association with PD in our 
Swedish case-control material, we cannot exclude these Rho GTPases as candidate genes for PD or other neurodegenera-
tive disorders. 
Keywords: Association, mitochondria, single nucleotide polymorphism. 
1. INTRODUCTION 
  Degeneration of dopamine (DA) neurons in substantia 
nigra (SN) pars compacta causes the typical motor symptoms 
seen in patients with Parkinson’s disease (PD); resting 
tremor, rigidity, bradykinesia and postural instability [1,2]. 
However, neuropathology in PD is widespread, affecting 
neurons in areas from the gastrointestinal tract to cerebral 
cortex [3]. In accordance with the systemic nature of the 
disease, there is increasing evidence that mitochondrial dys-
function may underlie some forms of PD [4-6]. Mitochon-
dria are essential in all eukaryotic cells for generating ATP, 
calcium buffering and involvement in programmed cell death 
[7-9]. To adapt to cellular demands mitochondria undergo 
fusion and fission, two opposing processes that exist in equi-
librium [10]. The mitochondrial network is very dynamic in 
neurons [11,12] and the rate of mitochondrial fusion and 
fission is high [13]. Recruitment of mitochondria to specific 
neuronal compartments has been shown to be an active ATP 
consuming process [14]. In support of a mitochondrial in-
volvement in PD, the metabolite of 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP), which is 1-methyl-4-
phenylpyridinium (MPP
+), is a neurotoxin and inhibits the 
mitochondrial respiratory chain complex I, which causes 
degeneration of DA neurons in SN [15]. Another inhibitor of 
complex I is the pesticide rotenone. In rodents it causes se-
lective degeneration of DA neurons, as well as other neurons 
to a lesser extent, thereby resembling the pathology of PD 
 
*Address correspondence to this author at the Department of Neuroscience, 
Karolinska Institutet, 171 77 Stockholm, Sweden; Tel: +46-8-524 870 51; 
Fax: +46-8-323 742; E-mail: andrea.carmine.belin@ki.se  
[16]. Complex I activity has been found to be reduced in SN 
and in platelets from PD patients [17].  
  Different polymorphisms in mtDNA have been reported 
to be associated with both increased and decreased risk of 
PD [18]. We and others have found associations between PD 
risk and two nuclear genes involved in mitochondrial main-
tenance,  MTIF3 (mitochondrial translation initiation factor 
3) and POLG1 (DNA polymerase gamma 1). MTIF3 is part 
of the initiation complex formation on the mitochondrial 55S 
ribosome and regulates translation of proteins within mito-
chondria [19,20]. A synonymous single nucleotide polymor-
phism (SNP) in MTIF3, rs7669, has been reported to be as-
sociated with PD in cohorts with different geographical ori-
gin [21-23]. POLG1 is important for replication and repair of 
the mitochondrial genome [24]. Variations in length of the 
polyglutamine tract of POLG1 have been found to associate 
with PD by a number of groups in different geographical 
regions [25-27]. 
  Several of the PARK genes identified by linkage studies 
have been reported to influence mitochondria in different 
ways. Mutations in PTEN induced putative kinase 1 (PINK1) 
at PARK6, reported to regulate mitochondrial fission, cause 
early-onset familial PD [28]. Mutations in Parkin at PARK2 
have been reported to cause autosomal recessive early-onset 
Parkinsonism [29]. Parkin acts in a similar way as PINK1 
[30] and is believed to be recruited from the cytoplasm by 
PINK1 to initiate autophagic degradation of impaired mito-
chondria [31]. DJ-1 at PARK7 causes autosomal recessive 
early-onset Parkinsonism [32] and is suggested to operate in 
a parallel pathway to that of PINK1/Parkin to maintain mito-
chondrial function in oxidative environments [33]. Pink1 has 2     The Open Neurology Journal, 2012, Volume 6  Anvret et al. 
been shown to be part of a mitochondrial multi-protein com-
plex together with the atypical GTPases Miro1 and Miro2 
(mitochondrial Ras homolog gene family, member T1 and 
T2) and the adaptor protein Milton [34]. This suggests that 
Pink1 also plays a role in mitochondrial trafficking.  
  Miro1 and Miro2, also referred to as Rhot1 and Rhot2, 
belong to the mitochondrial Rho GTPase family and are in-
volved in axonal transport of mitochondria [35,36]. Miro1 
and Miro2 were first identified in yeast  [37] and later de-
scribed to share similarities with Rho GTPases [38]. Miro 
proteins have a C-terminal domain locating them to the mi-
tochondrial outer membrane, as well as two GTPase domains 
and two calcium binding EF-hands [36,37]. Calcium binding 
to the EF-hands regulates the trafficking of mitochondria 
along microtubules [39,40].  
  Based on the finding that mitochondrial dysfunction has 
been implicated in PD [4,41], the importance of Miro1 and 
Miro2 in mitochondrial transport [35,36] and the link be-
tween Miro and Pink1 [34], we analyzed SNPs in MIRO1 
and MIRO2 with regard to PD. We hypothesized that genetic 
variations in functionally important regions of these two 
genes might lead to disturbed mitochondrial trafficking, fu-
sion and/or fission disturbances in neurons and hence in-
crease the risk of neurodegenerative events, such as those 
observed in PD. We therefore investigated the possible asso-
ciation of five SNPs located in functional regions of the pro-
teins MIRO1 and MIRO2. The SNPs were selected from the 
NCBI database and screened in a Swedish Parkinson case-
control material (see Table 1). Three SNPs were selected in 
MIRO1, one synonymous SNP in the GTPase domain 
(rs16967164) and two non-synonymous SNPs in each of the 
two EF-hands (rs28630420, rs34538349). The other two 
SNPs were non-synonymous SNPs located in one of the EF-
hand domains of MIRO2 (rs1139897 and rs3743912).  
2. MATERIALS AND METHODOLOGY 
2.1. Subjects 
  A Swedish PD case-control material of Caucasian origin 
was genotyped for three SNPs in MIRO1 and two in MIRO2 
(see Table 1). The PD material consisted of 241 individuals 
from the Stockholm area (mean age 67.0 years, 60.9% men). 
The DNA was obtained after informed oral and written con-
sent and approval of the local ethics committee, Regionala 
etikprövningsnämnden, Stockholm, Sweden. All PD subjects 
met the United Kingdom Parkinson's Disease Society Brain 
Bank Criteria for PD except that more than one affected first, 
second or third degree relative was allowed [42]. Control 
subjects consisted of 307 neurologically healthy spouses of 
PD patients and individuals from the SNAC-K project (The 
Swedish National Study on Aging and Care in Kungshol-
men) from the Stockholm area (mean age 64.2 years, 40.4% 
men). DNA was extracted from blood according to standard 
protocols.  
2.2. Genotyping 
  The SNPs were genotyped with predesigned TaqMan 
SNP Genotyping Assays: C_1630552_10 (rs16967164), 
C_60583023_10 (rs28630420), C_25937296_10 
(rs3743912), C_2463996_1_ (rs1139897) and a custom de-
signed assay (rs34538349) using a fast real-time PCR in-
strument (ABI 7500 FAST Real-Time PCR, Applied Biosys-
tems, Foster City, CA, USA). The TaqMan assay contained 
primers and 5´ fluorescently labeled (FAM and VIC) minor 
groove binding probes (20×) for detection of the SNPs. Alle-
lic discrimination was run with pre- and custom-designed 
primers and probes, genotyping master mix (TaqMan
®, Ap-
plied Biosystems, Foster City, CA, USA) and 10-20 ng of 
genomic DNA in a total reaction volume of 10 µl mixed in 
transparent 96-well plates. The polymerase chain reaction 
(PCR) conditions followed the recommendations of default 
settings for the SNP assay, except that the number of cycles 
were set to 55 and run at 92°C for 15 s. The ramp speed was 
set to standard. A post-PCR read was done for allelic dis-
crimination using appropriate software (SDS version 2.0.4) 
supplied with the instrument. To test for genotyping errors 
we used water as negative controls and re-genotyped ran-
domly chosen samples to confirm the results. Case-control 
analysis between individual sequence variants in MIRO1 and 
MIRO2 were performed using a Chi-square (χ
2) test [43]. 
Three PD patients previously known to carry the pathogenic 
G2019S mutation in leucine-rich repeat kinase 2 (LRRK2) 
were excluded from the association analysis. Distribution of 
genotypes in controls was tested for consistency with the 
Hardy-Weinberg equilibrium. Statistical significance was 
defined as p< 0.05.  
Table  1.  Investigated Polymorphisms in MIRO1 and MIRO2,  their Nucleotide Position, Consequence, Genomic Location and 
Functional Protein Region 
Reference Sequence  Nucleotide Position and Change  Amino Acid Change  Genomic Location  Protein Domain 
MIRO1 
rs16967164  c.1458A>G  Glu486Glu  Exon 17  GTPase domain 
rs28630420  c.766A>T   Thr256Ser  Exon 11  EF-hand 
rs34538349 c.1048_1049insT  Cys350Leu  Exon  13  EF-hand 
MIRO2 
rs1139897 c.734G>A  Arg245Gln  Exon  10  EF-hand 
rs3743912  c.708C>T   Asn236Asn  Exon 10  EF-hand MIRO1 and MIRO2 in Parkinson’s Disease  The Open Neurology Journal, 2012, Volume 6    3 
3. RESULTS 
  The results from the TaqMan genotyping of the five 
SNPs in MIRO1 and MIRO2 are presented in Table 2. We 
did not find any genotypic or allelic (data available upon 
request) association of the MIRO1 or MIRO2 SNPs screened 
in our Swedish Parkinson case-control material. The ob-
served frequencies of the controls were in agreement with 
the Hardy-Weinberg equilibrium (data not shown). For two 
of the SNPs in MIRO1 (rs28630420, rs34538349) we only 
observed the wild-type genotype.  
  To investigate if any of the SNPs had a possible effect on 
age of onset we stratified the material into early disease on-
set (≤50 years) or late disease onset (>50 years) and com-
pared genotype and allele frequencies. However, such strati-
fication did not reveal any significant associations with dis-
ease at genotype or allele (data available upon request) lev-
els, as shown in Table 3.  
4. DISCUSSION 
  Dysfunctional mitochondria may be the cause or the con-
sequence of DA neuron degeneration in PD. This is the first 
genetic study analyzing possible links between the two 
GTPases MIRO1 and MIRO2 and disease in general and neu-
rodegenerative disease in particular. Two functionally impor-
tant regions in the two Miro proteins are the two GTPase 
domains and two calcium binding EF-hands [36,37]. An-
other protein with a GTPase domain linked to PD is leucine-
rich repeat kinase 2 (LRRK2), a large protein with multiple 
domains, including functional Roc GTPase and a protein 
kinase domain. Several mutations in the kinase domain of 
LRRK2 are associated with both sporadic and familial PD 
[44]. Recently, a new mutation (N1437S) localized within 
the GTPase domain of LRRK2 (PARK8) was found to co-
segregate with PD  [45]. Furthermore, it has been suggested 
that the GTPase domain may contribute to the toxicity of 
LRRK2  [46]. Interestingly, knockdown of lrk-1, the 
ortholog of LRRK2 in C. elegans, has been reported to lead 
to reduced survival and is associated with dysfunctional mi-
tochondria  [47]. There are no reports on proteins with EF-
hand domains being linked to PD today.  
  It has been shown that all domains of Gem1P (i.e. yeast 
Miro) are needed for proper mitochondrial morphology [37]. 
Loss-of-function mutations in the Miro GTPase in Droso-
phila melanogaster lead to impaired locomotion and prema-
ture death of the flies  [48]. Based on these findings we se-
lected polymorphisms that are located in functional regions 
in MIRO1 and MIRO2 to analyze possible association with 
risk for neurodegeneration. The three selected MIRO1 SNPs 
are localized in one of the GTPase domains (rs16967164) 
and in each of the two EF-hands (rs28630420, rs34538349). 
The two SNPs in MIRO2 (rs1139897 and rs3743912) are 
situated in one of the EF-hand domains. We did not find as-
sociation with any of the selected SNPs in our Swedish case-
control material. For two of the SNPs in MIRO1 
(rs28630420 and rs34538349) we only detected the wild-
Table 2.  Genotype Frequencies of MIRO1 and MIRO2 Variants in Swedish Patients with Parkinson´s Disease (PD) Compared to 
Matched Neurologically Healthy Controls Analyzed using a Two-sided Chi-square (
2) test 
  Genotype Frequency % (n)  
2  P-value 
MIRO1 
rs16967164  AA AG GG     
PD   66.1 (152)  30.9 (71)  3 (7)  0.09  0.96 
Control   66.3 (203)  31.1 (95)  2.6 (8)     
rs28630420  AA AT TT    
PD   100 (235)  0 (0)  0 (0)  -  - 
Control  100 (300)  0 (0)  0 (0)     
rs34538349  -/- -/T  T/T    
PD   100 (236)  0 (0)  0 (0)  -  - 
Control  100 (306)  0 (0)  0 (0)     
MIRO2 
rs1139897  GG GA AA    
PD  57.3 (133)  34.9 (81)  7.8 (18)  2.03  0.36 
Control  51.1 (155)  40.3 (122)  8.6 (26)     
rs3743912  CC CT TT    
PD  73.5 (169)  24.8 (57)  1.7 (4)  0.87  0.65 
Control  76.9 (233)  21.8 (66)  1.3 (4)     4     The Open Neurology Journal, 2012, Volume 6  Anvret et al. 
Table 3.  Stratification of Parkinson’s Disease (PD) Cases into Early (≤50 years) and Late Onset (>50 years), Comparing MIRO1 
and MIRO2 Genotype Frequencies Analyzed using a Two-sided Chi-square (
2) Test 
  Genotype Frequency % (n)  
2  P-value 
MIRO1 
rs16967164 AA  AG  GG    
≤50 PD  62.3 (33)  40.0 (18)  3.8 (2)  0.45  0.80 
>50 PD  66.7 (118)  31.1 (55)  2.2 (4)  0.06  0.97 
Controls  66.3 (203)  31.1 (95)  2.6 (8)     
MIRO2 
rs1139897 GG  GA  AA     
≤50 PD  49.1 (26)  45.3 (24)  5.7 (3)  0.79  0.67 
>50 PD  59.6 (106)  32.0 (57)  8.4 (15)  3.51  0.17 
Controls  51.1 (155)  40.3 (122)  8.6 (26)     
rs3743912 CC  CT  TT     
≤50 PD  77.4 (41)  22.6 (12)  0  -  - 
>50 PD  72.2 (127)  25.6 (45)  2.3 (4)  1.63  0.44 
Controls  76.9 (233)  21.8 (66)  1.3 (4)     
type genotype in our material of cases and controls. Thus 
these two mutations tend to be very rare in the area from 
which our DNA samples have been collected. The results 
after stratification of the material regarding age of onset did 
not reveal any age-of-onset association with any of the de-
tected polymorphisms. Further genetic analysis and func-
tional studies in disease are however needed before one can 
exclude MIRO1 and MIRO2 as potential candidate genes for 
PD. 
CONCLUSION 
 Genetic  variation  in  MIRO1 and MIRO2 might influence 
transport of mitochondria along microtubules, leading to 
reduced local energy production which can lead to degenera-
tion of DA neurons. Although we did not find a significant 
association with PD and the selected polymorphisms in 
MIRO1 and MIRO2 in our Swedish case-control material, we 
cannot exclude these Rho GTPases as candidate genes for 
PD or other neurodegenerative disorders.  
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